Cadent Capital Advisors LLC Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Cadent Capital Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 71,100 shares of the company’s stock, valued at approximately $1,310,000.

A number of other large investors also recently bought and sold shares of the business. Carnegie Investment Counsel bought a new position in Hims & Hers Health in the 3rd quarter worth about $5,531,000. Diversify Advisory Services LLC bought a new position in Hims & Hers Health in the first quarter worth approximately $701,000. Sei Investments Co. increased its holdings in Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the period. Quantbot Technologies LP raised its position in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after purchasing an additional 208,621 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after buying an additional 328,142 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several recent research reports. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Bank of America boosted their price objective on shares of Hims & Hers Health from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Jefferies Financial Group increased their target price on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $20.07.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total transaction of $47,738.99. Following the sale, the insider now directly owns 172,274 shares of the company’s stock, valued at $3,516,112.34. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,609 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the transaction, the chief financial officer now directly owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total transaction of $47,738.99. Following the completion of the sale, the insider now directly owns 172,274 shares in the company, valued at $3,516,112.34. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 835,911 shares of company stock valued at $14,640,096. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $22.15 on Friday. The business’s 50-day moving average is $16.94 and its 200 day moving average is $17.59. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a market capitalization of $4.76 billion, a P/E ratio of 276.91 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.03) earnings per share. On average, analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.